戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed to be proxies for functional variation in CYP2A6.
2 stallography and compared with structures of CYP2A6.
3 ulations due to differences in metabolism by CYP2A6.
4 es NNK with much lower K(m) values than does CYP2A6.
5 activity relationship (SAR) of inhibition of CYP2A6.
6 19 but differed by sex (females: rs11878604, CYP2A6 (~ 16 kb 3'), for C vs. T: beta = - 0.71, P = 6.6
7  nicotine complexes with CYP2A13 (2.5 A) and CYP2A6 (2.3 A) yield a structural rationale for the pref
8 nal analysis, including the deletion variant CYP2A6*4 (beta = -0.90, p = 1.55 x 10(-11)).
9  with the top causal configuration including CYP2A6*4, rs116670633, CYP2A6*9, rs28399451, rs8192720,
10 16.2% variation explained; males: rs3865454, CYP2A6 (~ 7 kb 3'), for G vs. T: beta = 0.64, P = 1.9e-1
11 ), 9 [DBH] (p-value = 9.69 x 10(-9)) and 19 [CYP2A6/7] (p-value = 3.49 x 10(-8)) and for FEV1/FVC on
12 nfiguration including CYP2A6*4, rs116670633, CYP2A6*9, rs28399451, rs8192720, and rs10853742 (PP = 0.
13                                              CYP2A6, a genetically variable enzyme, inactivates nicot
14  was characterized and compared with that of CYP2A6, a human ortholog of rat CYP2A3, which has been d
15 e to genetic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2.
16                   Evidence is presented that CYP2A6 accommodates multiple ligands and that intramolec
17                 Causal effects of phenotypic CYP2A6 activity (measured as the nicotine metabolite rat
18     These findings support a role for faster CYP2A6 activity as a causal risk factor for lung cancers
19     In the total sample and current smokers, CYP2A6 activity causal estimates on the six PWS signals
20 tensity accounted for 82.3% of the effect of CYP2A6 activity on lung cancer risk but entirely mediate
21  respiratory diseases PheCodes, where faster CYP2A6 activity was associated with greater disease risk
22 f our weighted genetic risk score (wGRS) for CYP2A6 activity with diseases in the UK Biobank (N = 395
23 ine at inhibition of coumarin 7-hydroxylase (CYP2A6) activity.
24  disease susceptibility (HHIP, IREB2/CHRNA3, CYP2A6/ADCK, TGFB2, and MMP12).
25 the predictive model by including additional CYP2A6 alleles improves the fit of the model in an indep
26  simplify the range of function of different CYP2A6 alleles, their numerous possible diplotype combin
27               Amino acid differences between CYP2A6 and CYP2A13 at positions 117, 300, 301, and 208 r
28 redox transitions of the haem domain in both CYP2A6 and CYP2A6-FLD.
29  the product were performed with immobilized CYP2A6 and CYP2A6-FLD.
30  recombinant human enzymes demonstrated that CYP2A6 and CYP2B6 oxidized PCB 91 and PCB 132 in the met
31                  These findings suggest that CYP2A6 and CYP2B6 play an important role in the oxidatio
32 enes encoding nicotine-metabolizing enzymes (CYP2A6 and CYP2B6) and nicotinic acetylcholine receptor
33 450 enzymes were screened: drug-metabolizing CYP2A6 and CYP2D6 and sterol-metabolizing CYP8B1.
34 is of a previous study, we hypothesized that CYP2A6 and CYP2E1 accommodate multiple xylene ligands.
35 at P450 enzymes bound to either b5 alpha4-5 (CYP2A6 and CYP2E1) or this region and alpha2-3 (CYP2D6 a
36 on of cytotoxicity and inhibition of hepatic CYP2A6 and CYP3A4 showed that 44 fulfills first safety c
37               Here, we demonstrate that when CYP2A6 and EGLN2 genotypes are analyzed together, the ke
38                    Although both the hepatic CYP2A6 and respiratory CYP2A13 enzymes metabolize these
39 rst reported electrochemical signal of human CYP2A6 and to improve its catalytic efficiency on electr
40                                Lung CYP2A13, CYP2A6, and CYP2A7 (and CYP1A2) mRNA levels in smokers a
41 (1.04- to 1.12-fold) levels of lung CYP2A13, CYP2A6, and CYP2A7 (and higher CYP1A2) mRNA.
42 ated with a reduction in human lung CYP2A13, CYP2A6, and CYP2A7 mRNA, consistent with the role of nic
43 ol and AV cues can package altered levels of CYP2A6, and cytokines/chemokines in plasma EVs that may
44   This region includes RAB4B, EGLN2, MIA and CYP2A6, and has previously been identified in associatio
45                                  CYP2A13 and CYP2A6 are expressed in the lung and may contribute to l
46 olized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.
47 elective enzymatic CYP inhibitors identified CYP2A6 as the major isoform involved in this process.
48 new lead variants near CHRNA5 at 15q25.1 and CYP2A6 at 19q13.2 associated with lung cancer and TRIP13
49 ated with nicotine metabolism independent of CYP2A6, but is nevertheless independently associated wit
50                                A significant CYP2A6-by-smoking status interaction was found (Psintera
51  that compliment the active site features of CYP2A6 can exhibit significant selectivity for CYP2A6 re
52 13850 T allele rescued the downregulation of CYP2A6 caused by cigarette smoke exposure, potentially t
53                               The CYP2A3 and CYP2A6 cDNAs were cloned into baculovirus, and recombina
54                  X-ray crystal structures of CYP2A6 cocrystallized with three furan analogues bearing
55 human CYP2A subfamily comprises three genes, CYP2A6, CYP2A7, and CYP2A13.
56 this methylation-based screen--the vanin and CYP2A6-CYP2A7 gene clusters--both implicated in traits o
57 etaDrug software suggested a role of CYP1A2, CYP2A6, CYP2B6, CYP2E1, and CYP3A4 in the metabolism of
58  Apo-b(5) enhances the activities of CYP3A4, CYP2A6, CYP2C19, and CYP17A1 but not that of CYP2E1 or C
59           A predictive model that translates CYP2A6 diplotype into a single continuous variable was p
60                                  Because the CYP2A6 effect was seen only in smokers, these data sugge
61 cotinine/cotinine) is a stable biomarker for CYP2A6 enzyme activity and nicotine clearance, with demo
62                  Thirteen were receiving the CYP2A6 enzyme inhibitor isoniazid, and all 15 were genot
63   Nicotine is inactivated by the polymorphic CYP2A6 enzyme to cotinine and then to 3'hydroxycotinine.
64                                              CYP2A6 exhibited cooperative kinetics for m-xylene-alpha
65 DRD2 exhibits significant homophily and that CYP2A6 exhibits significant heterophily.
66 ta: rs113288603 is associated with increased CYP2A6 expression in cerebellar hemispheres (p = 7.8 x 1
67  electrochemical activity of the immobilized CYP2A6-FLD, toward both coumarin and nicotine substrates
68  with a higher efficiency by the immobilized CYP2A6-FLD, with a calculated kcat value significantly h
69 vibrio vulgaris (FLD) to create the chimeric CYP2A6-FLD.
70 itions of the haem domain in both CYP2A6 and CYP2A6-FLD.
71 t were performed with immobilized CYP2A6 and CYP2A6-FLD.
72                             Variation in the CYP2A6 gene alters the rate of nicotine metabolic inacti
73 es because of polymorphic differences in the CYP2A6 gene.
74 erved in rat CYP2A3, mouse Cyp2a5, and human CYP2A6 genes and was found to be essential for transcrip
75                The causal pathway connecting CYP2A6 genetic variability and activity, cigarette consu
76                                              CYP2A6 genotype is not associated with nicotine dependen
77  the contribution of nicotine metabolism and CYP2A6 genotype to lung cancer risk, particularly with r
78                                A significant CYP2A6 genotype x smoking effect was found in the dorsal
79 he relationship between Cytochrome P450 2A6 (CYP2A6) genotype and smoking phenotypes made comparisons
80                   Thus, rat CYP2A3 and human CYP2A6 have differences in substrate specificity as well
81 ers, with 6 participants additionally having CYP2A6 heterozygous genotype.
82 hylphenylamine but was much less active than CYP2A6 in coumarin 7-hydroxylation.
83                      Moreover, expression of CYP2A6 in plasma EVs was significantly increased after s
84 , the expressed CYP2A13 was more active than CYP2A6 in the metabolic activation of hexamethylphosphor
85                                 Variation in CYP2A6 influences smoking behaviors and tobacco-related
86 , by tranylcypromine, a potent and selective CYP2A6 inhibitor.
87   The inhibitory activity of the most potent CYP2A6 inhibitors on the functional activity of human cy
88 19 locus was found (top variant: rs56113850, CYP2A6 (intronic), for C vs. T: females: beta = 0.67, P
89 he conclusion that the finding is related to CYP2A6 involvement in nicotine metabolism.
90                                              CYP2A6 is active toward many carcinogens and is the majo
91                     Another cytochrome P450, CYP2A6, is also present in human lung, but at much lower
92 nhibited coumarin 7-hydroxylation by RLM and CYP2A6 (Ki, 3000 and 320 microM, respectively).
93 eing highly putatively causal and mapping to CYP2A6, MAP3K10, ADCK4, and CYP2B6.
94 ation and supported findings that CYP2D6 and CYP2A6 mediated this reaction.
95 ted with structural changes in the brain and CYP2A6 mediates these changes.
96  AHR), 15q24 (near CYP1A2) and 19q13.2 (near CYP2A6) met GW-significance (P < 5 x 10-8) and were asso
97                         Additionally, faster CYP2A6 metabolizer status was associated with younger ag
98 ge was compared between faster versus slower CYP2A6 metabolizers for the PWS signals in survival anal
99 sly reported in a region of 19q13, including CYP2A6 (nicotine metabolism enzyme) and EGLN2 (hypoxia r
100 s, and ( k H/ k D) obs values for CYP2E1 and CYP2A6 oxidation of m-xylene-alpha- (2)H 3 and p-xylene-
101 iovisual cue modulates nicotine-metabolizing CYP2A6, oxidative stress modulators, and cytokines/chemo
102 91 and PCB 132 in the meta position and that CYP2A6 oxidized PCB 95 and PCB 136 in the para position.
103 asure of hepatic nicotine metabolism via the CYP2A6 pathway and total nicotine clearance, is a predic
104 or deciphering the metabolic implications of CYP2A6 polymorphism and for the screening of CYP2A6 subs
105 favirenz exposure were defined by CYP2B6 and CYP2A6 polymorphisms.
106              Common genetic variation in the CYP2A6 region is strongly associated with NMR in smokers
107 ive independent associations with NMR in the CYP2A6 region were identified using stepwise conditional
108 les and SNPs underlie the association of the CYP2A6 region with NMR among African American smokers, i
109 , and several exhibited high selectivity for CYP2A6 relative to CYP2E1, -3A4, -2B6, -2C9, -2C19, and
110 P2A6 can exhibit significant selectivity for CYP2A6 relative to other human liver drug-metabolizing P
111 identified a significant association between CYP2A6 rs113288603 and hearing loss symptoms (p = 5.75 x
112 YP2B6 (rs3745274, rs28399499, rs4803419) and CYP2A6 (rs28399433) were selected and used to determine
113 king behavior, such as those with CHRNA5 and CYP2A6, showed population specificity.
114              We evaluated the association of CYP2A6 single-nucleotide polymorphisms (SNPs) and * alle
115 er, under the same conditions, the levels of CYP2A6, SOD1, and catalase were only markedly altered.
116         As expected, the overall CYP2A13 and CYP2A6 structures are very similar with an average root
117 CYP2A6 polymorphism and for the screening of CYP2A6 substrates and inhibitors.
118 tress related proteins, cytochrome P450 2A6 (CYP2A6), superoxide dismutase-1 (SOD1), catalase (CAT).
119                                         Like CYP2A6, the CYP2A13 active site cavity is small and high
120 nomics of this highly heritable biomarker of CYP2A6, the main metabolic enzyme for nicotine, will als
121                         This work shows that CYP2A6 turnover efficiency is improved when the protein
122 highly selective for the inhibition of human CYP2A6 versus the other human CYPs examined.
123   Km for rat CYP2E1, human CYP2E1, and human CYP2A6 was 210, 115, and 17 microM, respectively (Vmax:
124                           On the other hand, CYP2A6 was active toward coumarin but not toward testost
125  the selectivity of the phenyl analogues for CYP2A6 was decreased relative to the pyridyl compounds.
126                 In contrast, the activity of CYP2A6 was only weakly inhibited by metyrapone or methox
127 ariant rs56113850 C>T located in intron 4 of CYP2A6 was significantly associated with decreased lung
128 tochrome P450 Family 2 Subfamily A Member 6 (CYP2A6), we investigated the human phenome in a total of
129 didate SNPs, 2 (rs12459249, rs11667314) near CYP2A6 were expression quantitative trait loci in lung t
130 ll microsomal fractions containing CYP2A3 or CYP2A6 were studied in a reconstituted system with purif
131 ignificantly higher (P < 0.005) than that of CYP2A6, whereas the affinity for the substrate (KM) rema

 
Page Top